I ❤️ imatinib I ❤️ venetoclax I ❤️ ATRA/ATO I ❤️ Rituximab I ❤️ PTCy 💪🏽

Final chance to register for our free one-hour webinar on respiratory viral infections in hematological patients. Taking place on April 22 at 16:00 (CEST), the webinar will feature Jon Salmanton Garcia, Chair of the EHA-SWG on Infections in Hematology, as the speaker. Register

Share this graphic to show your support for #AMLWorldAwarenessDay! More “I'm supporting AML World Awareness Day” graphics are available at loom.ly/V_TCShs #KnowAML

Check out our new article in JAMA! Practical advice on Factor V Leiden testing. tinyurl.com/mt3f83ah

#EHA2025 is a unique career opportunity for early-career professionals to connect with the global hematology community. With a full-day YoungEHA Research Meeting program, Education Sessions, opportunities to network, and the latest clinical and research data this is your

#EHA is a space for career growth, learning, and connection, and #YoungEHA sessions are no different. From addressing burnout to hematology in outer space, this year's sessions will bring you new perspectives from the field from June 12-15. Register now: eha.fyi/EHA2025_regist…

Screening for monoclonal gammopathy of undetermined significance is contraindicated buff.ly/13LCjeJ

Hem/oncs carry not only their own burdens, but also the weight of their patients' and their families' struggles. It's not just making the diagnosis and treating by the protocols...it's understanding person across you, fighting for funds, for studies and loads of bureaucracy 💪🏻

Another successful and fruitful conference, another great 4 days... European Hematology Association is raising the standards higher and higher every year ☺️ #EHA2025 Darko Antic Danijela Lekovic Vladimir Otasevic

Za #urgentnicentar KCS sve pohvale, ljudi rade, ne staju.

Immune thrombocytopenia (ITP) is an autoimmune disorder that causes low platelet counts. Curious about the cause of low platelets in ITP? Watch the video to learn more about the pathophysiology of this rare disease #ISTH2025. This is intended for US health care professionals.

🫁 A COPD-specific diagnostic strategy for PE was retrospectively validated and found to be safe using a 3-item score + D-dimer with 2 cut-offs, 50% of patients avoided imaging. 🔍 Signs of DVT, non-purulent AECOPD, and PE as most likely dx #ISTH2025 #VTE #COPD

New Special Issue in IJMS MDPI: Biomarkers for Precision Medicine in Cancer-Associated Thrombosis! Submit your work by 11/30/2025. Info here: [mdpi.com/si/244531] #cancerresearch #thrombosis #biomarkers

Presented at #ESCCongress: In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results:

🩸🔍 Anticoagulation & Bone Marrow Biopsy – Is it safe? 📌 Background •BM biopsy = most common hematology diagnostic procedure. •Complication = bleeding (rare but potentially severe). •Effect of anticoagulation on bleeding risk = unclear. Guidelines = inconsistent . 📊

Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) nej.md/4p6tIDo Editorial: Art within Evidence — Balancing Anticoagulant Duration in VTE Care nej.md/3HDriLB #ESCCongress | European Society of Cardiology

🔴 September is #BloodCancerAwarenessMonth At EBMT, we join the global effort to increase public understanding of blood cancers and highlight the importance of early diagnosis. Through collaborative science and clinical expertise, we are committed to advancing research,

Thank you so much for helping us raise awareness of ALL! #acutelymphoblasticleukemia

🌟 Upcoming career development webinar! Join us for a special ISTH–European Hematology Association Career Development Webinar: “Hematology Research – For Patients, With Patients” 🗓️ Don’t miss this opportunity to learn, connect and grow in your career: bit.ly/42RJSqr